• Serious Side Effect Sidelines Gene-Edited Sickle Cell Therapy from Graphite Bio

    20 days ago - By MedCity News

    Graphite Bio voluntarily paused a Phase 1/2 test of its gene-edited therapy for sickle cell disease after the first patient in the study developed a serious blood complication. The setback will also delay plans to reach the clinic with another genetic medicine in its pipeline.
    Read more ...